key: cord-0332363-r1p79lr7
authors: Tsuchida, Yumi; Shoda, Hirofumi; Nakano, Masahiro; Ota, Mineto; Okamura, Tomohisa; Yamamoto, Kazuhiko; Kurano, Makoto; Yatomi, Yutaka; Fujio, Keishi; Sawada, Tetsuji
title: Autotaxin may play a Critical Role between the Genetic Risk Factors and Pathogenesis of SLE in Plasmacytoid Dendritic Cells
date: 2021-10-25
journal: bioRxiv
DOI: 10.1101/2021.10.25.465592
sha: 0611003474924e7f0159bbb1f23812de527299c0
doc_id: 332363
cord_uid: r1p79lr7

The importance of autotaxin, which catalyzes the production of lysophospholipids, has recently been recognized in various diseases including cancer and autoimmune diseases. We herein report our analysis of autotaxin in systemic lupus erythematosus (SLE), utilizing data from ImmuNexUT, a comprehensive database consisting of transcriptome data and expression quantitative trait locus (eQTL) data of immune cells from patients with immune-mediated disorders. Autotaxin was elevated in the serum of SLE patients, and the expression of ENPP2, which encodes autotaxin, is elevated in plasmacytoid dendritic cells (pDCs) of SLE patients compared to healthy controls. In weighted correlation network analysis, ENPP2 belonged to a module that correlated with disease activity. This module was enriched in interferon-associated genes and included genes whose expression is influenced by SNPs associated with SLE, suggesting that it is a key module connecting genetic risk factors of SLE with disease pathogenesis. The increased expression of ENPP2 in pDCs from SLE patients may be due to increased expression of interferon-associated genes and increased binding of STAT3 complexes to the regulatory region of ENPP2. Thus, autotaxin may play a critical role in connecting genetic risk factors of SLE to disease pathogenesis in pDCs.

Lysophospholipids (LPLs) are phospholipids with only one fatty acid chain, including Sphingosine-1-Phosphate (S1P), lysophosphatidic acids (LPA), and lysophosphatidylserine. By signaling through their respective G protein-coupled receptors, they play important roles in various biological processes 1 4 . Also, it has been reported that autotaxin is increased in the urine of patients with lupus nephritis 5 . Therefore, autotoxin could be important in the pathogenesis of SLE; however, the exact role of autotaxin in the pathogenesis of SLE remains unclear.

Both genetic and environmental factors contribute to the development of SLE.

Various genome wide association studies have been performed to identify genetic risk factors for SLE, and more than 100 loci have been reported to be associated with SLE 6 .

However, the exact mechanism by which those GWAS SNPs contribute to the development of SLE in often not clear, and further studies are necessary to elucidate the link between genetic risk factors of SLE and disease pathogenesis and to develop new treatment strategies.

Recently, our group has created a transcriptome and eQTL database of immune cells from various immune-mediated diseases, "ImmuNexUT" 7 . This database consists of the genome and transcriptome of 28 immune cells from patients with various immune-mediated diseases, as well as healthy controls (HC). Here, to further elucidate the pathogenic role of autotaxin in SLE, we utilized the data from ImmuNexUT 7 to examine the expression pattern of autotaxin in immune cells, its relationship to clinical parameters, and genetic risk factors of SLE.

First, we examined the concentration of autotaxin in the serum of untreated SLE patients and HC. As the serum concentration of autotaxin is reported to be different between females and males 8 , females and males were analyzed separately. The serum concentration of autotaxin was higher in SLE patients compared to HC in both females (Fgure 1a) and males (Figure 1b) .

Next, we utilized the transcriptome data of SLE patients and age and sex matched HC from ImmuNexUT to examine the mRNA expression level of ENPP2, which encodes autotaxin. The expression of ENPP2 was high in plasmacytoid dendritic cells (pDCs) compared to other immune cell subsets, as reported previously 7,9 ( Figure   2a ). Therefore, we focused on pDCs, and the expression of ENPP2 was elevated in pDCs of SLE patients compared to HC, as noted by others 9 (Figure 2b ). When the transcriptome of pDCs from females and males were analyzed separately, ENPP2 was also identified as differentially expressed gene (DEG) in both females ( Figure 2c ) and males ( Figure 2d ).

To further examine the role of ENPP2 in the pathogenesis of SLE, weighted correlation network analysis (WGCNA) was performed to group genes into modules of genes with similar expression patterns, using RNA-seq data of pDCs from SLE patients.

( Figure 3a ). ENPP2 belonged to the magenta module (Supplementary Table S2) , and the eigengene score of this module showed correlation with SLEDAI-2K, as well as anti-RNP antibody positivity (Figure 3a ). The eigengene score of this module was high in patients with moderate or high disease activity (SLEDAI-2K > 6) compared to patients with mild or no disease activity (SLEDAI-2K ≤ 6) ( Figure 3b ). The magenta module included many interferon-associated genes, such as IFIH1 and ISG15, and pathway analysis of the genes in this module showed enrichment of interferon-associated pathways ( Figure 3c ).

Further examination of the members of the magenta module using the eQTL database from ImmuNexUT 7 indicated that this module contains genes whose expression is influenced by SLE GWAS SNPs in pDCs. For example, rs13385731, in LD with SLE GWAS SNP rs13425999 10 , is an expression quantitative trait locus (eQTL) of RASGRP3 in pDCs (Figure 4a ). That is, in patients with the SLE risk allele, the expression of RASGRP3 is increased in pDCs. In addition, rs11059921, in LD with SLE GWA SNP rs11059919 11 , influences the expression of SLC15A4, suggesting that this module may reflect the link between genetic risk factor of SLE and disease pathogenesis (Figure 4b ).

Next, to elucidate the mechanism for the increased expression of ENPP2 in pDC of SLE patients, we examined the eQTL database in ImmuNexUT. rs11778951, located in the ENPP2 gene, influenced the expression of ENPP2 in pDCs with the G allele increasing the expression of ENPP2 (Figure 5a ). ATAC-seq data of immune cells from a public database 12 indicated that rs11778951 coincides with a peak specific in pDCs ( Figure 5b ). This locus was predicted to be a distal enhancer-like signature in ENCODE 13 and resided near predicted IRF1 and STAT3 binding sites 14 . Furthermore, rs11778951 alters a STAT binding motif at this site 15 . Therefore, the increase in interferon signaling in SLE patients may cause increased binding of STAT3 complexes to this site in pDCs, leading to the increased expression of ENPP2.

We herein describe our analysis of autotaxin and related pathways using the ImmuNexUT database. Autotaxin is elevated in the serum of SLE patients, and the expression of ENPP2, encoding autotaxin, is increased in pDCs of SLE patients. WGCNA analysis indicated that the expression of ENPP2 correlates with the magenta module, whose members are enriched in interferon-associated genes and whose expression correlates with disease activity of SLE. The magenta module included genes whose expression are affected by SLE GWAS SNPs, suggesting that ENPP2 may be one of the key molecules linking genetic risk factors of SLE with disease pathogenesis. Furthermore, rs11778951, which coincides with an ATAC-seq peak specific to pDCs, alters STAT protein binding motifs, has an eQTL effect on ENPP2, suggesting that the increased interferon signaling in SLE patients may contribute to the increased expression of ENPP2 in SLE.

This study has suggested important points regarding the role of autotaxin in SLE.

It has been reported that autotaxin is highly expressed in adipose tissue, central nervous system, and reproductive organs 16 , and in the immune system, autotaxin is expressed by endothelial cells in high endothelial venules. Dendric cells has not generally gained much attention as an important source of autotaxin; however, a recent report regarding the role of autotaxin in COVID19 has suggested that autotaxin expressed by pDC may affect the development and function of DCs by regulating the local production of LPA 9 . Our study suggests that the increased expression of autotaxin in pDCs of SLE patients may contribute to pathophysiology of SLE through altered DC function, as well.

Our study indicated that the expression of interferon associated genes show correlation with the expression of ENPP2 in pDCs. A role for type I interferons in the production of autotaxin has previously reported 17 , and our results are consistent with this.

Furthermore, by combining WGCNA analysis with eQTL database, a potential mechanism for increased expression of ENPP2 in pDCS in SLE patients was identified.

That is, the increase in interferon-signaling induced by genetic risk factor of SLE may lead to the increased expression of ENPP2 in pDCs by increasing the binding of STAT proteins to rs11778951, an eQTL locus of ENPP2 in pDCs.

In conclusion, our transcriptome analysis of pDC identified a gene module, whose expression correlates with disease activity in SLE patients and is affected by SLE GWAS SNPs. By examining genes in this module, autotaxin expressed by pDC was identified as a possible key molecule in the link between genetic risk factors and pathogenesis of SLE. Serum autotaxin was quantified by one-step immunoenzymometric assay, as described elsewhere 8 . In brief, a pair of rat monoclonal antibodies (mAb) specific for human autotaxin was used for the two-site immunoassay. The autotaxin immunoassay reagents containing magnetic polymer beads coated with the primary mAb, and an alkaline phosphatase-labeled secondary mAb were placed in the reaction cup. After addition of diluted serum sample into the reaction cup, the resulting assay reagent was applied to a commercial automated immunoassay analyzer (AIA-2000 system; Tosoh, Tokyo, Japan).

For the differential gene expression analysis, RNA-seq data from the ImmuNexUT study 7 was utilized. Details of the sample collection, RNA-sequencing, and data processing have been described in detail previously 7 . SLE patients with expression data for pDCs after filtering were included (n=59), and 51 healthy controls, age and gender matched to the SLE patients, were selected as controls. The SLE patients fulfilled the American College of Rheumatology (ACR) 1997 classification criteria 18 and SLICC 2012 criteria 19 . Patients with malignancies, acute infections, or those taking with more than 20 mg prednisolone were excluded. Disease activity was assessed with SLEDAI-2K 20 . Differential expression analysis was performed with edgeR after TMM normalization 21 .

For weighted gene co-expression network analysis (WGCNA) analysis, genes with read counts less than 10 in 90% or more of the samples were excluded. Count data was normalized with TMM normalization and converted to log 2 (CPM + 1). WGCNA was performed using WGCNA package version 1.68 with signed network and soft thresholding power set to 8. One sample was excluded as an outlier. The representative expression value of each module, "eigengenes", were calculated, and the correlation between eigengenes and clinical parameters were assessed. Pathway analysis was performed by DAVID 22 using REACTOME pathways 23 .

For the eQTL analysis, the eQTL data from ImmNexUT database were utilized, and the details are described in the initial study 7 . After filtering out genes expressed with low expression in each cell subset, the expression data were normalized with TMM normalization, converted to CPM and normalized across samples using an inverse normal transform. Probabilistic Estimation of Expression Residuals (PEER) method 24 was used to find hidden covariates. An QTLtools permutation pass with 10,000 permutations was used to obtain gene-level nominal P value thresholds corresponding to FDR < 0.05 for each cell subset. Then, a forward-backward stepwise regression eQTL analysis was performed with a QTLtools conditional pass. ATAC-seq data from the report by Calderon et al. 12 was used to assess the relationship of eQTL SNPs with ATAC-seq peaks. Data regarding candidate cis-regulatory elements from the ENCODE study was utilized for the visualization of distal enhancer like signatures 25 , and data from JASPAR 14 was used to visualize predicted transcription factor binding sites.

The ethics committees at the University of Tokyo Hospital and the Tokyo Medical University Hospital approved this study, and written consent was obtained from all participants (G10095).

Categorical data were tested with Fisher's exact test. Differences between two groups were compared with t-tests for normally-distributed continuous data and with Mann-Whitney U tests for non-normally distributed continuous data. Correlations were evaluated with Spearman's rank correlation coefficients. P values less than 0.05 were considered significant. Statistical analyses were performed with R version 3.5.0 (R Foundation for Statistical Computing). 

Lysophospholipids and their G protein-coupled receptors in inflammation and immunity

Association between serum autotaxin or phosphatidylserine-specific phospholipase A1 levels and melanoma

Higher serum levels of autotaxin and phosphatidylserine-specific phospholipase A(1) in patients with lupus nephritis

Serum phosphatidylserine-specific phospholipase A(1) as a novel biomarker for monitoring systemic lupus erythematosus disease activity

Urinary autotaxin concentrations are associated with kidney injury

The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus

Dynamic landscape of immune cell-specific gene regulation in immunemediated diseases

Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation

Increased Autotaxin Levels in Severe COVID-19

Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells

Evaluation of SLE Susceptibility Genes in Malaysians

Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus

Landscape of stimulation-responsive chromatin across diverse human immune cells

Expanded encyclopaedias of DNA elements in the human and mouse genomes

JASPAR 2020: update of the open-access database of transcription factor binding profiles

HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants

Autotaxin and chronic inflammatory diseases

Type I Interferons Function as Autocrine and Paracrine Factors to Induce Autotaxin in Response to TLR Activation

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up

Systemic lupus erythematosus disease activity index 2000

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

DAVID-WS: a stateful web service to facilitate gene/protein list analysis

The reactome pathway knowledgebase

Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses

Systematic discovery and characterization of regulatory motifs in ENCODE TF binding experiments

We would like to express our gratitude to all the study participants for their cooperation for this study. The supercomputing resource, SHIROKANE, was provided by the Human Genome Center, The University of Tokyo. This study was supported by Chugai Pharmaceutical Co., Ltd.